List of partners

The following companies and organisations have confirmed their participation in the 30th ECNP Congress.

In alphabetical order:  


Stand number: 4

Angelini is a privately held international company. Founded in Italy in 1919, Angelini has branches in 20 countries and employs 5,000 people. Pharma is the group’s core business, representing over 50% of the company’s € 1.5 billion 2015 revenue. Angelini focuses its research and commercial activities mainly on infection, pain and inflammation, and CNS diseases and disorders.



CINP - International College of Neuropsychopharmacology
Stand number: 25

The International College of Neuropsychopharmacology (CINP) is a truly worldwide membership organisation established over 50 years ago. Membership is on an individual basis. We offer members the opportunity to become part of this knowledgeable group of scientists, to participate at our meetings, and to publish in our own IJNP.



concentris research management gmbh           
Stand number: 14

concentris is specialized in the management of EU-funded research projects.
We carry out the non-scientific tasks of funded research projects and provide support and consultancy services for scientists and researchers at universities, in businesses and research institutes from the first project idea to the successful completion.



DGPPN - The German Association for Psychiatry, Psychotherapy and Psychosomatics
Stand number: 21

From anxiety disorder to obsessive-compulsive disorder, from science to care – the DGPPN Congress gathers all the expertise in psychiatry and psychotherapy in one place. Thanks to its broad range of topics, renowned experts and excellent continuing education opportunities, it has established itself as a central forum for the field of mental health.



EBC - European Brain Council
Stand number: 24

The European Brain Council (EBC) is a non-profit organisation gathering patient associations, major brain-related societies and companies. Its mission is to promote brain research in order to improve the quality of life of those living with brain disorders in Europe. 165 million Europeans have a brain disorder, costing more than EUR 800 billion annually.  



EPA - European Psychiatric Association
Stand number: 26

With active individual members in as many as 88 countries and 40 National Society/Association Members who represent more than 78,000 European psychiatrists, the European Psychiatric Association is the main association representing psychiatry in Europe. EPA’s activities address the interests of psychiatrists in academia, research and practice throughout all stages of career development.



Stand number: 20

EUFAMI is an international NGO based in Belgium committed to improving the care and welfare for people with mental illness.
Our mission is to represent at the European level all family members of persons that are affected by mental illness and to protect their rights and interests.



FENS - Federation of European Neuroscience Societies
Stand number: 19

FENS is the voice of European neuroscience. With 43 neuroscience member societies across 33 European countries, FENS as an organisation represents 24,000 European neuroscientists with a mission to advance European neuroscience education and research. FENS promotes neuroscience research to policy-makers, funding bodies and the general public, both regionally and internationally.



Stand number: 23

GAMIAN-Europe (Global Alliance of Mental Illness Advocacy Networks-Europe), a patient-driven pan-European organization, represents the interests of persons affected by mental illness and advocates for their rights. Its main objectives are: advocacy, information and education, anti-stigma and discrimination, patients’ rights, co-operation, partnerships and capacity building.



Gedeon Richter Plc. 
Stand number: 7
Satellite symposium: C.08

Headquartered in Hungary, Gedeon Richter is an innovation-driven specialty pharmaceutical company. It has manufacturing subsidiaries in five countries and markets its products in one hundred countries. Its latest achievement in R&D is the original antipsychotic compound, cariprazine, already marketed in the US for the treatment of bipolar mania and schizophrenia.



H. Lundbeck A/S
Stand number: 2 and 3
Satellite symposia: C.01, C.03, C.04, C.05 and C.09
Expert science exchange: CE.01 and CE.03

Lundbeck – improved treatment and a better life for people living with psychiatric and neurological disorders. A global pharmaceutical company specialised in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research in neuroscience with focus on depression, schizophrenia, Parkinson's disease and Alzheimer's disease.



Stand number: 5
Satellite symposium: C.10

At Janssen, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We collaborate with the world for the health of everyone in it. Follow us at



Stand number: 18
Expert science exchange: CE.05 

LivaNova exists at the intersection of advancing technology and transforming lives for people impacted by difficult to treat depression, drug resistant epilepsy, cardiopulmonary diseases and cardiac rhythm disorders. We develop Vagus Nerve Stimulation, the first approved adjunctive long-term treatment option, offering sustained efficacy and increased quality of life with a favourable safety profile and guaranteed compliance.  



Stand number: 16

Lucimed is a Belgian company that manufactures the Luminette, a pair of light therapy glasses used to fight seasonal affective disorder (SAD) and circadian disorders (sleep, jet-lag, shift work). The Luminette was born in 2006 after four years of university research in Liège, Belgium.



Lundbeck Institute
Stand number: 2

Our mission is to develop and cascade unbiased, evidence-based medical education in psychiatry and neurology from leading experts to health care professionals and create a forum to facilitate knowledge-sharing. Since 1997 we have been committed to providing expert, international, interactive seminars, thereby building a valued legacy in medical education.


   Lundbeck Institute

Stand number: 28

Monsenso is an innovative technology company offering an mHealth solution to help optimise the treatment of mental disorders. Our mission is to help clinicians, researchers, and individuals overcome the burden of mental illness.



NbN - Neuroscience-based Nomenclature
Stand number: 11

The Neuroscience-based Nomenclature (NbN) is an ECNP-led international collaboration established to align the nomenclature of psychotropic drugs with the neuroscience underlying them. The new nomenclature encompasses all medications with CNS indications and is now available to clinicians for free download on the iOS App Store and the Google Play Store.


  NBN logo new 2017 

Stand number: 15

NEUROFIT, your worldwide preferred partner (CRO) in the evaluation of treatments for central and peripheral nervous system disorders. We offer a comprehensive validated list of in vitro and in vivo models fully adapted to your needs. Our goal is to accelerate the development of your programmes by providing cost-effective methods.



Otsuka Pharmaceutical Europe Ltd
Stand number: 3
Satellite symposia: C.03 and C.09
Expert science exchange: CE.01

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health worldwide.’ Otsuka’s 45,000 employees ensure that patients have access to innovative products and medical devices in our therapy areas of central nervous system disorders, endocrinology, nephrology, gastroenterology and oncology.



Pfizer Inc.
Expert science exchange: CE.02 

At Pfizer, we apply science and our global resources to bring therapies that extend and significantly improve people's lives. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.


Stand number: 9

Porsolt provides efficacy and safety pharmacology, covering the drug development process from early screening through to regulatory submission. Porsolt also provides in vitro assays (high throughput screening, high content analysis, and high content histology) and physiopathological models in multiples species and multiple disease areas, tailored solutions and bespoke model development.



PRA Health Sciences
Stand number: 17

Over the last 30 years, PRA Health Sciences has built the most comprehensive, high-end Early Development Services group in the world. Our pharmacology experts deliver innovative solutions from state-of-the-art facilities in Europe and North America. PRA also operates GLP-compliant laboratories close to the clinical units, enabling us to quickly analyse time-critical samples.



Pronexus Analytical AB
Stand number: 12

Pronexus Analytical is a preclinical CRO offering services in CNS pharmacology, neurochemistry and bioanalysis, with a focus on PK/PD studies and in vivo microdialysis in experimental models of CNS and metabolic disorders. The bioanalytical services include UHPLC-MS/MS, HPLC, and immunoassays for measuring disease biomarkers and drug levels in biological samples.



Stand number: 7
Satellite symposium: C.08

Recordati is a European specialty pharmaceutical group dedicated to partnering, discovering and developing innovative, value-added products. Recordati is committed to the research and development of treatments for rare diseases, new specialties within the urological area and in psychiatry commercialising cariprazine, a novel atypical antipsychotic drug for the treatment of schizophrenia.



Stand number: 1
Satellite symposium: C.07

Servier is at the forefront of research and education in the neurosciences, with heavy investment in neuropharmacology for the treatment of brain diseases: depression, Alzheimer's and Parkinson's diseases, and schizophrenia. The most recent result of our research is agomelatine, an antidepressant indicated in the treatment of patients with major depressive episodes.



Expert science exchange: CE.04

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialised conditions. We strive to develop best-in-class products across our core therapeutic areas, including haematology, immunology, neuroscience, ophthalmics, lysosomal storage disorders, gastrointestinal/internal medicine/endocrine, hereditary angioedema, and oncology.



Sooma Medical
Stand number: 27

Sooma Medical develops non-invasive neuromodulation devices for treatment of neurological and psychiatric disorders. The treatment utilises a mild form of brain stimulation known as transcranial direct current stimulation (tDCS). Patients in over 25 countries have benefited from Sooma Depression Treatment since it was approved in 2014.



Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.
Satellite symposium: C.02

Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US. Sumitomo Dainippon Pharma Co., Ltd. is among the top-ten listed pharmaceutical companies in Japan operating globally. Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US.



Sunovion Pharmaceuticals Europe Ltd.
Stand number: 6
Satellite symposium: C.02

Sunovion Pharmaceuticals Europe, headquartered in London, is a wholly owned subsidiary of Sunovion Pharmaceuticals Inc. Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US.



The Lancet
Stand number: 8

The Lancet is the world's leading, independent general medical journal, publishing original primary research and review articles of the highest standard. Since its inception in 1823, the journal has sought to address urgent topics in health and society, initiate debate, put science into context, and influence decision makers around the world.



WFSBP Congress 2019 - 14th World Congress of Biological Psychiatry
Stand number: 22

During the upcoming World Congress of Biological Psychiatry in Vancouver, worldwide opinion leaders will share with us the recent innovations in their respective fields which impact on diagnosis, treatment and quality of life of our patients. High scientific level sessions will be organised: plenary lectures, symposia, interactive workshops and debates.



Wisepress Medical Bookshop
Stand number: 10, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of the ECNP Congress available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.